Fulcrum Therapeutics Statistics
Total Valuation
FULC has a market cap or net worth of $253.21 million. The enterprise value is -$74.24 million.
Important Dates
The next estimated earnings date is Tuesday, July 28, 2026, before market open.
| Earnings Date | Jul 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
FULC has 66.63 million shares outstanding. The number of shares has increased by 7.54% in one year.
| Current Share Class | 66.63M |
| Shares Outstanding | 66.63M |
| Shares Change (YoY) | +7.54% |
| Shares Change (QoQ) | +15.86% |
| Owned by Insiders (%) | 1.20% |
| Owned by Institutions (%) | 89.46% |
| Float | 41.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.76 |
| P/TBV Ratio | 0.76 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 34.33, with a Debt / Equity ratio of 0.02.
| Current Ratio | 34.33 |
| Quick Ratio | 33.97 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -27.10% and return on invested capital (ROIC) is -18.79%.
| Return on Equity (ROE) | -27.10% |
| Return on Assets (ROA) | -18.36% |
| Return on Invested Capital (ROIC) | -18.79% |
| Return on Capital Employed (ROCE) | -25.69% |
| Weighted Average Cost of Capital (WACC) | 19.82% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.38M |
| Employee Count | 55 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -46.93% in the last 52 weeks. The beta is 2.91, so FULC's price volatility has been higher than the market average.
| Beta (5Y) | 2.91 |
| 52-Week Price Change | -46.93% |
| 50-Day Moving Average | 5.83 |
| 200-Day Moving Average | 8.51 |
| Relative Strength Index (RSI) | 37.24 |
| Average Volume (20 Days) | 5,377,950 |
Short Selling Information
The latest short interest is 7.99 million, so 12.00% of the outstanding shares have been sold short.
| Short Interest | 7.99M |
| Short Previous Month | 7.80M |
| Short % of Shares Out | 12.00% |
| Short % of Float | 19.05% |
| Short Ratio (days to cover) | 14.73 |
Income Statement
| Revenue | n/a |
| Gross Profit | -56.78M |
| Operating Income | -86.55M |
| Pretax Income | -76.12M |
| Net Income | -76.12M |
| EBITDA | -85.18M |
| EBIT | -86.55M |
| Earnings Per Share (EPS) | -$1.14 |
Full Income Statement Balance Sheet
The company has $333.32 million in cash and $5.87 million in debt, giving a net cash position of $327.45 million or $4.91 per share.
| Cash & Cash Equivalents | 333.32M |
| Total Debt | 5.87M |
| Net Cash | 327.45M |
| Net Cash Per Share | $4.91 |
| Equity (Book Value) | 333.30M |
| Book Value Per Share | 5.00 |
| Working Capital | 328.81M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$63.56 million and capital expenditures -$322,000, giving a free cash flow of -$63.88 million.
| Operating Cash Flow | -63.56M |
| Capital Expenditures | -322,000 |
| Depreciation & Amortization | 1.38M |
| Net Borrowing | n/a |
| Free Cash Flow | -63.88M |
| FCF Per Share | -$0.96 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |